Personalized and precision medicine as a unique avenue to have th | 60475
Journal of Cell Science & Therapy

Journal of Cell Science & Therapy
Open Access

ISSN: 2157-7013

Personalized and precision medicine as a unique avenue to have the healthcare model renewed to secure the national biosafety: To get cancer treated or cured?

16th World Congress on Tissue Engineering, Regenerative Medicine and Stem Cell Research & 6th World Congress on Oncology and Cancer Research

May 12, 2022 | Joint Webinar

Sergey Suchkov

Institute for Global Health of MGUPP and A.I. Evdokimov MGMSU, Russia

Keynote: J Cell Sci Ther

Abstract :

A new systems approach to diseased states and wellness result in a new branch in the healthcare services, namely, personalized and precision medicine (PPM). Personalized and Precision Oncology (PPO) is an innovative approach to cancer management that ensures your treatment is specifically designed and targeted to your unique form of cancer. The latter are both the science of using each patient’s individual genomic landscapes – the genes that are mutated, causing the cancer to grow – to create a biomarker-based targeted therapy protocol. To achieve the implementation of PPM and PPO concept, it is necessary to create a fundamentally new strategy based upon the recognition of biomarkers long before the disease clinically manifests itself. And personalized tumor molecular profiles (uniting genomic and phenotypic ones), tumor disease site and other patient characteristics are then potentially used for determining optimum individualized (preventive, prophylactic, canonical and rehabilitative) therapy options to be tailored and applied for. Each decision-maker values the impact of their decision to use PPM/PPO on their own budget and well-being, which may not necessarily be optimal for society as a whole. It would be extremely useful to compile and integrate available scientific knowledge on cancer-associated abnormal genes and gene products and their implications for cancer therapy, and thus data harvesting from different databanks for applications such as prediction and personalization of further treatment to thus provide more tailored measures for the patients resulting in improved patient outcomes, reduced adverse events, and more cost effective use of the latest health care resources including diagnostic (companion ones), preventive and therapeutic (targeted molecular and cellular) etc. The latter requires the incorporation of information from multiple data sources, linking the functional effects of altered genes to potential therapy options into a central repository that can be easily accessed, interpreted, and utilized by physicians and patients. This complex and unique process provides a thorough and fairly exhaustive resource for physicians and patients to use as a PPM-based cancer therapy option that is designed to be highly clinically applicable. PPM/PPO are most likely to play a great role in cancer management and treatment. And we are entering an era of rapidly evolving transformation in cancer research as it relates to medical practice, and a shifting paradigm of standardized health care in which detailed genetic and molecular information regarding a patient’s cancer is being used for PPM/PPM-based treatments. Meanwhile, a lack of the medical guidelines has been identified by the majority of responders as the predominant barrier for adoption, indicating a need for the development of best practices and guidelines to support the implementation of PPM/PPO! So, coordination of all health care stakeholders has become more important than ever to unite oncologists, pathologists, and payers to work with Big Pharma and Biotech to develop products, services, and coverage policies that would improve patient outcomes and lower overall health care costs for institutions that put personalized regimens in place. This is the reason for developing global scientific, clinical, social, and educational projects in the area of PPM/ PPO to elicit the content of the new branch and to stress the impact and benefits of the latter.

Biography :

Sergey Suchkov is currently the Professor, Director of Center for Personalized Medicine, Sechenov University and Dept of Clinical Immunology, A.I.Evdokimov Moscow State Medical and Dental University; Professor, Chair, Dept for Translational Medicine, Moscow Engineering Physical Institute, Russia; Secretary General, United Cultural Convention, Cambridge, UK. Also he is a member of the New York Academy of Sciences, USA; American Chemical Society, USA; American Heart Association, USA; European Association for Medical Education, Dundee, UK; European Association for Predictive, Preventive and Personalized Medicine, Brussels, EU; American Association for Research in Vision and Ophthalmology; International Society for Eye Research; Personalized Medicine Coalition, Washington, USA. Finally Dr Suchkov is a member of the Editorial Boards of “Open Journal of Immunology”, EPMA J., American J. of Cardiovascular Research and “Personalized Medicine Universe”..